Insiders at MediWound (NASDAQ: MDWD) buy 11,200 shares at $17.74

Rhea-AI Filing Summary

MediWound Ltd. reports that its Chairman, Nachum (Homi) Shamir, and Chief Executive Officer, Ofer Gonen, each individually purchased the company’s ordinary shares in open market transactions on August 18, 2025. These insider purchases totaled 11,200 ordinary shares at an average price of $17.74 per share.

The company states that all trades complied with its insider trading policy. This report is also being used to incorporate its contents by reference into multiple existing MediWound registration statements on Forms S-8 and F-3 filed with the SEC.

Form 6-K: How Foreign Companies Report to the SEC →

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549
______________________

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934

For the month of August 2025

Commission File Number: 001-36349

MediWound Ltd.
(Translation of registrant’s name into English)

42 Hayarkon Street

Yavne, 8122745 Israel

 (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒          Form 40-F ☐

CONTENTS

MediWound Ltd. (the “Company”) is filing this Form 6-K to report that on August 18, 2025, Mr. Nachum (Homi) Shamir, Chairman of the Company’s Board of Directors, and Mr. Ofer Gonen, the Company’s Chief Executive Officer, each individually purchased ordinary shares of the Company in open market transactions.

These purchases totaled 11,200 ordinary shares at an average purchase price of $17.74 per share and were conducted in compliance with all applicable requirements of the Company’s insider trading policy.

The contents of this Report of Foreign Private Issuer on Form 6-K, are hereby incorporated by reference into the Company’s Registration Statements on Form S-8 filed with the SEC on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020, May 15, 2021 August 9, 2022, August 15, 2023, and March 19, 2025 (Registration Nos. No. 333-195517, 333-210375, 333-223767, 333-230487, 333-236635, 333-255784, 333-266697, 333-273997 and 333-285897, respectively) and on Form F-3 filed with the SEC on March 31, 2023,  August 29, 2024 and March 19, 2025 (Registration Nos. 333-268297, 333-281843 and 333-285908, respectively).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	MEDIWOUND LTD.
Date: August 19, 2025	By:	/s/ Hani Luxenburg
	Name:	Hani Luxenburg
	Title:	Chief Financial Officer

FAQ

What insider share purchases did MediWound (MDWD) disclose in its August 2025 Form 6-K?

MediWound disclosed that two senior executives bought company shares in the open market. On August 18, 2025, combined insider purchases totaled 11,200 ordinary shares, reflecting direct market buying rather than option exercises or grants, at a disclosed average purchase price of $17.74 per share.

Who bought MediWound (MDWD) shares and how many were purchased?

The filing states that Chairman Nachum (Homi) Shamir and Chief Executive Officer Ofer Gonen each individually purchased MediWound ordinary shares. Together, their open market transactions amounted to 11,200 ordinary shares, showing direct personal share acquisitions by the company’s top leadership on August 18, 2025.

At what price were the MediWound (MDWD) insider shares purchased?

MediWound reports that the insider purchases were made at an average price of $17.74 per ordinary share. This average price applies to the total of 11,200 shares acquired in open market transactions by the company’s Chairman and Chief Executive Officer on August 18, 2025.

Did MediWound (MDWD) confirm compliance with insider trading rules for these purchases?

Yes. MediWound states the purchases were conducted in compliance with all applicable requirements of its insider trading policy. This indicates the company considers the open market transactions by its Chairman and Chief Executive Officer properly authorized and consistent with its internal governance procedures.

How does this Form 6-K relate to MediWound’s existing registration statements?

The company specifies that the contents of this Form 6-K are incorporated by reference into several MediWound registration statements. These include multiple Forms S-8 dating from 2014 through 2025 and Forms F-3 filed in 2023, 2024, and 2025, updating those documents with this information.

What type of SEC filing did MediWound (MDWD) use to report these insider purchases?

MediWound used a Form 6-K, which is a report of a foreign private issuer, to disclose the insider open market purchases. The filing highlights the August 18, 2025 transactions by the Chairman and Chief Executive Officer and formally records them with the U.S. Securities and Exchange Commission.